Novo Nordisk analysis favors Wegovy pill over orforglipron on weight loss
A Novo Nordisk cross-trial analysis says the Wegovy pill beat orforglipron on weight loss and side-effect stopping, but it is not a head-to-head study and cannot show which drug works better for one person.
Novo Nordisk said on April 2, 2026 that its once-daily Wegovy pill, oral semaglutide 25 mg, produced significantly greater average weight loss than orforglipron 36 mg, and that people taking orforglipron had roughly 14 times higher odds of stopping treatment because of gastrointestinal side effects [1].
The finding comes from what Novo Nordisk describes as a population-adjusted indirect treatment comparison, not a head-to-head clinical trial [1]. In an indirect comparison, results from separate studies are pooled and statistically adjusted for differences between the patients who took part, rather than patients being randomly assigned to one medicine or the other [1]. Novo Nordisk said the analysis used data from the OASIS 4 trial of oral semaglutide and the ATTAIN-1 trial of orforglipron [1].
The announcement came one day after the FDA approved orforglipron, which is sold as Foundayo [1]. Novo Nordisk makes the Wegovy pill, so the analysis was sponsored by a company with a commercial interest in the result [1]. The full analysis has not been published, and Novo Nordisk says it will be presented at the Obesity Medicine Association 2026 meeting [1]. The announcement did not include the size of the weight-loss difference in pounds or percentage points, and the meeting date has not been disclosed [1].
The Wegovy pill was approved by the FDA on Dec. 22, 2025, as the first oral GLP-1 for weight loss in adults [1]. It is supplied as 1.5 mg, 4 mg, 9 mg and 25 mg tablets and is taken once daily on an empty stomach [1]. In September 2025, Novo Nordisk reported that oral semaglutide 25 mg delivered 16.6% weight loss in people with obesity in a newly published study [1].
Wegovy tablets are also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight [1]. The label says the tablets are not recommended for use with other semaglutide products or with any other GLP-1 receptor agonist, and it carries a boxed warning for an increased risk of thyroid C-cell tumors [1]. Common adverse reactions reported in at least 5% of patients include nausea, diarrhea, vomiting, constipation, abdominal pain, headache and fatigue [1].
Why it matters for patients
People who prefer a daily pill to a weekly injection now have more than one oral GLP-1 option, and the two are being compared in public by the companies that sell them [1]. Because Novo Nordisk's analysis compares separate trials rather than randomly assigning patients to one drug or the other, it cannot show how an individual patient would respond to either medicine or which would be easier to tolerate [1]. Gastrointestinal side effects are the most common adverse reactions listed on the Wegovy label, so tolerability is already something patients and prescribers weigh when choosing a treatment [1].
The analysis did not address cost or insurance coverage [1]. Novo Nordisk has reduced US list prices for its semaglutide medicines and launched a multi-month subscription program, but how health plans will cover either oral drug has not been reported in this announcement [1].
What happens next
The analysis is scheduled to be presented at the Obesity Medicine Association 2026 meeting; a date has not been disclosed [1]. Whether the full results will be published in a peer-reviewed journal, and whether the two companies will run a head-to-head trial, have not been announced [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.